In order to increase the number of HER2-low BC patients suitable for inclusion in HER2-targeted therapy [73], several studies have started to classify all new possible HER2 subgroups by analyzing the clinical and molecular landscapes of HER2-low BC more accurately, where possible. The gene discussed is ERBB2; the disease is breast cancer.